Trial Profile
A randomized, open label, six sequences, cross-over study in healthy Japanese subjects to evaluate the pharmacokinetic comparability of deferasirox granule formulation with the reference dispersible tablet formulation (Exjade)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 11 Mar 2016
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Iron overload; Myelodysplastic syndromes
- Focus Pharmacokinetics
- Sponsors Novartis
- 11 Mar 2016 New trial record